Remove Biomarkers Remove Reimbursement Remove Strokes
article thumbnail

Biocardia Reports Positive Interim Results from Phase III Cardiamp Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure

DAIC

The CardiAMP HF trial is supported by the Maryland Stem Cell Research Fund and has reimbursement from the Centers for Medicare and Medicaid Services (CMS) for both treatment and control procedures. The CardiAMP HF II trial is expected to similarly secure CMS reimbursement. vs. 13.2%, respectively).

article thumbnail

American Heart Month Puts Spotlight on Cardiovascular Disease and Stroke Statistics

DAIC

February 1, 2024 — As cardiologists, heart disease patients and the organizations that serve them across the country embark on American Heart Month, DAIC has compiled a snapshot of significant cardiovascular disease (CVD) and stroke statistics, along with a review of the atherosclerosis drug market. per 1,000* - 122.4